News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Revenue from operations up 26% to Rs. 768 crores
Hello Patients provides healthcare billing and patients’ management solution
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated
